STELLA PHARMA CORPORATION AI Stock Analysis
Want to see JP:4888 full AI Analyst Report?
STELLA PHARMA CORPORATION (4888) AI Stock Analysis
STELLA PHARMA CORPORATION
(TSE/TYO:4888)
The overall score is very low, driven primarily by weak financial performance. The company is unprofitable, cash flow negative, and has highly volatile revenues, which are significant risks. While the balance sheet is manageable, it does not offset the core operational challenges. Technicals show some positive price momentum, but this is a secondary factor against the poor fundamentals and unattractive valuation.
STELLA PHARMA CORPORATION (4888) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 17.79B
- Dividend Yield
- ―
- Average Volume (3M)
- 621.95K
- Price to Earnings (P/E)
- -17.6
- Beta (1Y)
- 1.05
- Revenue Growth
- -69.92%
- EPS Growth
- -411.54%
- Country
- Japan
- Employees
- 47
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
STELLA PHARMA CORPORATION Business Overview & Revenue Model
Company Description
Stella Pharma Corporation is a pharmaceutical company that handles the complete process of drug development, from research and manufacturing to distribution. A core area of its specialization is in therapeutic agents for boron neutron capture therapy...
STELLA PHARMA CORPORATION Financial Statement Overview
Summary
Financial performance is weak. The income statement shows persistent losses and highly volatile revenue, with a 66% drop in the latest year. Cash flow is predominantly negative, indicating a cash-burning business. The balance sheet is the only relative bright spot, with manageable debt, but overall financial health is poor.
Income Statement
22NegativeBalance Sheet
58NeutralCash Flow
34Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 323.39M | 323.39M | 961.06M | 269.49M | 229.07M | 100.10M |
| Gross Profit | 264.07M | 250.56M | 828.72M | 203.69M | 192.36M | 50.73M |
| EBITDA | -832.87M | -742.15M | -99.06M | -723.85M | -738.35M | -726.86M |
| Net Income | -853.06M | -780.92M | -140.81M | -763.75M | -778.82M | -767.72M |
Balance Sheet | ||||||
| Total Assets | 5.39B | 4.49B | 5.42B | 3.82B | 4.33B | 4.72B |
| Cash, Cash Equivalents and Short-Term Investments | 3.80B | 2.82B | 3.21B | 2.35B | 2.71B | 3.28B |
| Total Debt | 899.48M | 747.14M | 766.78M | 933.30M | 1.09B | 1.25B |
| Total Liabilities | 2.17B | 2.06B | 2.21B | 1.44B | 1.58B | 1.64B |
| Stockholders Equity | 3.22B | 2.43B | 3.21B | 2.38B | 2.75B | 3.08B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -345.32M | 136.50M | -887.82M | -853.07M | -1.13B |
| Operating Cash Flow | 0 | -334.51M | 140.41M | -876.84M | -827.67M | -1.08B |
| Investing Cash Flow | 0 | -15.67M | 287.58M | -9.01M | -29.93M | -350.56M |
| Financing Cash Flow | 0 | -33.28M | 725.78M | 228.25M | 291.69M | 3.46B |
STELLA PHARMA CORPORATION Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4888, the sentiment is Positive. The current price of 460.00 is above the 20-day moving average (MA) of 395.35, above the 50-day MA of 403.90, and above the 200-day MA of 419.95, indicating a bullish trend. The MACD of -1.00 indicates Negative momentum. The RSI at 63.96 is Neutral, neither overbought nor oversold. The STOCH value of 74.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4888.
STELLA PHARMA CORPORATION Peers Comparison
Overall Rating
JP:488842Neutral
JP:777442Neutral
JP:457141Neutral
JP:459938Underperform
JP:459337Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 42Neutral | JPY 17.50B | -17.63 | ― | ― | -69.92% | -411.54% | |
| 42Neutral | JPY 25.58B | -69.38 | ― | ― | 17.05% | 10.47% | |
| 41Neutral | JPY 6.46B | -4.26 | -39.57% | ― | 48.92% | -46.91% | |
| 38Underperform | JPY 7.90B | -4.21 | ― | ― | ― | 4.85% | |
| 37Underperform | JPY 27.92B | -12.37 | ― | ― | -51.55% | 52.19% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4888 | STELLA PHARMA CORPORATION | 460.00 | 208.00 | 82.54% | |
| JP:4571 | NanoCarrier Co., Ltd. | 71.00 | -73.00 | -50.69% | |
| JP:4593 | Healios KK | 206.00 | -269.00 | -56.63% | |
| JP:4599 | StemRIM Inc. | 126.00 | -152.00 | -54.68% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 630.00 | 145.00 | 29.90% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 18, 2026
